Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Treasury Shares (2021 - 2026)

Centessa Pharmaceuticals has reported Treasury Shares over the past 5 years, most recently at $1.0 million for Q3 2025.

  • Quarterly Treasury Shares rose 637.18% to $1.0 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $1.0 million through Sep 2025, up 637.18% year-over-year, with the annual reading at $1.5 million for FY2024, 387.04% up from the prior year.
  • Treasury Shares was $1.0 million for Q3 2025 at Centessa Pharmaceuticals, down from $1.1 million in the prior quarter.
  • Over five years, Treasury Shares peaked at $2.4 million in Q1 2024 and troughed at $34746.0 in Q1 2025.
  • The 5-year median for Treasury Shares is $965056.0 (2021), against an average of $1.1 million.
  • The largest YoY upside for Treasury Shares was 637.18% in 2025 against a maximum downside of 98.58% in 2025.
  • A 5-year view of Treasury Shares shows it stood at $982944.0 in 2021, then plummeted by 39.02% to $599421.0 in 2022, then tumbled by 48.27% to $310052.0 in 2023, then soared by 387.04% to $1.5 million in 2024, then crashed by 31.43% to $1.0 million in 2025.
  • Per Business Quant, the three most recent readings for CNTA's Treasury Shares are $1.0 million (Q3 2025), $1.1 million (Q2 2025), and $34746.0 (Q1 2025).